Q2 2026 Fennec Pharmaceuticals Inc. Earnings Call Transcript
Key Points
- Record Q2 2026 net product sales of $17.1 million, a 78% year-over-year increase, driven by strong demand and a 143% revenue increase since 2024.
- Achieved seventh consecutive quarter of growth, with record patient enrollment, infusions, and new customers in July 2026, indicating sustained momentum.
- Expanded commercial reach with a 280% increase in sales calls and a target base growth from 1,300 to 5,000 prescribers, enhancing market penetration.
- Positive clinical and regulatory progress, including NCCN 2A recommendation for AYA patients, multiple investigator-sponsored studies (ISTs) across tumor types, and an oral presentation at SIOP 2026 for PEDMARK's pharmacokinetic data.
- Strong financial position with $41.2 million in cash, record non-GAAP adjusted EBITDA of $2.8 million, and a positive EPS of $0.05, reflecting improved profitability and cash flow.
- No formal revenue guidance provided for 2026, with management only hinting at potential guidance for 2027, leaving investors without clear forward-looking targets.
- Expected Q3 2026 cash position to be lower than Q2 due to collection cycles, indicating potential short-term cash flow volatility.
- Dependence on investigator-sponsored studies (ISTs) for label expansion and NCCN guideline updates, which are subject to enrollment timelines and regulatory approval, creating uncertainty.
- Increased operating expenses, with a $3.6 million year-over-year rise in OpEx, driven by marketing and headcount investments, which may pressure near-term profitability.
- Limited progress on in-licensing complementary products, with management noting no suitable opportunities yet, potentially limiting portfolio diversification and long-term growth.
Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals' second-quarter 2026 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
Now, I'd like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.
Thank you, operator, and good morning, everyone. We would like to thank you for joining us. We are pleased to host Fennec Pharmaceuticals' second-quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update.
Joining me from Fennec this morning is our Chief Executive Officer and Board member, Jeff Hackman; our Chief Commercial Officer, Terry Evans; and our Chief Medical Officer, Dr. Pierre Sayad. I am also pleased to welcome our Chief Strategy Officer, Christi Cioffi, who is joining our earnings call for the first time.
Christi has more than two decades of leadership
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
